FORBES-TATE
Lobbying for PHRMA · A trade group representing the pharmaceutical research and biopharmaceutical companies
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.